Key Points
- CEO Katherine Stueland sold 3,639 shares on December 9 at an average price of $159.28 for about $579,620, reducing her ownership by 36.45% to 6,344 shares (valued ~ $1.01M).
- GeneDx recently reported a quarterly beat with EPS $0.49 vs. $0.28 expected and revenue of $116.74M vs. $104.33M, with a net margin of 0.52% and ROE of 20.22%.
- The stock trades around $155, has a market cap of $4.49B and an outsized reported P/E (~1,726), and carries a consensus rating of "Moderate Buy" with an average price target of $133.11.
GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CFO Kevin Feeley sold 1,266 shares of the firm's stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $159.28, for a total transaction of $201,648.48. Following the transaction, the chief financial officer owned 5,389 shares of the company's stock, valued at approximately $858,359.92. This trade represents a 19.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Kevin Feeley also recently made the following trade(s):
- On Wednesday, October 29th, Kevin Feeley sold 388 shares of GeneDx stock. The stock was sold at an average price of $136.54, for a total transaction of $52,977.52.
- On Tuesday, September 16th, Kevin Feeley sold 3,728 shares of GeneDx stock. The stock was sold at an average price of $121.47, for a total transaction of $452,840.16.
GeneDx Trading Down 0.6%
GeneDx stock opened at $154.48 on Friday. The firm has a market cap of $4.47 billion, a price-to-earnings ratio of 1,741.48 and a beta of 1.99. GeneDx Holdings Corp. has a 1 year low of $55.17 and a 1 year high of $170.87. The firm's 50 day moving average price is $138.59 and its two-hundred day moving average price is $112.98. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.59 and a current ratio of 2.71.
GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings data on Tuesday, October 28th. The company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.21. The business had revenue of $116.74 million during the quarter, compared to analyst estimates of $104.33 million. GeneDx had a return on equity of 20.22% and a net margin of 0.52%. On average, research analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.
Institutional Trading of GeneDx
A number of hedge funds have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of GeneDx by 5.1% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company's stock worth $399,000 after purchasing an additional 181 shares during the period. Jones Financial Companies Lllp lifted its position in GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company's stock worth $25,000 after buying an additional 186 shares in the last quarter. Quarry LP boosted its stake in shares of GeneDx by 248.8% during the 3rd quarter. Quarry LP now owns 293 shares of the company's stock valued at $32,000 after buying an additional 209 shares during the period. Chung Wu Investment Group LLC grew its holdings in shares of GeneDx by 8.2% during the 2nd quarter. Chung Wu Investment Group LLC now owns 3,300 shares of the company's stock valued at $305,000 after acquiring an additional 250 shares in the last quarter. Finally, Kovack Advisors Inc. increased its stake in shares of GeneDx by 14.3% in the third quarter. Kovack Advisors Inc. now owns 2,868 shares of the company's stock worth $309,000 after acquiring an additional 358 shares during the last quarter. 61.72% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
WGS has been the topic of a number of analyst reports. BTIG Research lifted their price target on GeneDx from $165.00 to $200.00 and gave the stock a "buy" rating in a research note on Friday. Zacks Research downgraded shares of GeneDx from a "strong-buy" rating to a "hold" rating in a research report on Thursday, October 2nd. Wall Street Zen lowered shares of GeneDx from a "buy" rating to a "hold" rating in a report on Saturday, November 1st. Wells Fargo & Company raised their price objective on shares of GeneDx from $95.00 to $140.00 and gave the stock an "equal weight" rating in a research note on Tuesday, November 4th. Finally, Guggenheim reiterated a "buy" rating and set a $170.00 price objective (up from $115.00) on shares of GeneDx in a research report on Wednesday, October 29th. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, GeneDx has a consensus rating of "Moderate Buy" and an average price target of $133.11.
Check Out Our Latest Analysis on WGS
About GeneDx
(
Get Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
